Skip to main content

Table 1 Baseline characteristics of the study participants

From: Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes

  n = 101
Age (years) 65.6 ± 11.3
Male sex 76 (75.2%)
Etiology
 Ischemic heart disease 46 (45.5%)
 Dilated cardiomyopathy 18 (17.8%)
 Hypertensive cardiomyopathy 8 (7.9%)
 Alcoholic cardiomyopathy 7 (6.9%)
 Valvular disease 8 (7.9%)
 Hypertrophic cardiomyopathy 4 (4.0%)
 Other 10 (9.9%)
HF duration in months 38.7 (12.7–77.4)
LVEF 41.8% ± 12.1
NYHA functional class
 I 9 (8.9%)
 II 70 (69.3%)
 III 22 (21.8%)
Co-morbidities
 Hypertension 74 (73.3%)
 Diabetes mellitus 50 (49.5%)
 Renal failurea 48 (47.5%)
 Anemiab 41 (40.6%)
 Atrial fibrillation/flutter 42 (41.6%)
Obesity 31 (30.7%)
Smoker
 Current 4 (4.0%)
 Past 66 (65.3%)
Treatments
 ACEI/ARB 89 (88.1%)
 Beta-blockers 93 (92.1%)
 MRA 63 (62.4%)
 Loop diuretics 81 (80.2%)
 Digoxin 21 (20.8%)
 Ivabradine 19 (18.8%)
 Statins 86 (85.1%)
 ICD 3 (3.0%)
 CRT 16 (15.8%)
  1. Data expressed as mean ± standard deviation, median (25th–75th percentiles), or absolute number (percentage)
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CRT cardiac resynchronization therapy, ICD implantable cardioverter device, LVEF left ventricular ejection fraction, MRA mineral corticoid receptor antagonist, NYHA New York Heart Association
  3. aeGFR < 60 ml/min/1.73 m2
  4. bHb of < 12 g/dl in women and < 13 g/dl in men